Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors.
Clinical and immunologic implications of COVID-19 in patients with melanoma and renal cell carcinoma receiving immune checkpoint inhibitors.
复制标题
DOI：
10.1136/jitc-2021-002835
复制
发表时间：
2021-07
影响因子：
10.9
通讯作者：
Turajlic S
中科院分区：
文献类型：
--
作者：
Switzer B;Haanen J;Lorigan PC;Puzanov I;Turajlic S
SARS-CoV-2大流行对接受全身抗癌治疗的癌症患者的临床和免疫学影响带来了大量的临床挑战和学术争议。本文综述了SARS-CoV-2大流行期间癌症患者使用免疫检查点抑制剂（ICI）的现有证据、讨论要点和建议，重点关注黑色素瘤和肾细胞癌（RCC）患者。更具体地说，我们总结了关于ICI与抗病毒免疫应答之间关系的理论概念和可用的客观数据，沿着推荐的在COVID-19大流行期间管理接受ICI的黑色素瘤和RCC患者队列的临床方法。还讨论了关于在当前和即将到来的COVID-19疫苗的背景下使用ICI的其他见解以及对未来大流行病的更广泛影响。
The clinical and immunologic implications of the SARS-CoV-2 pandemic for patients with cancer receiving systemic anticancer therapy have introduced a multitude of clinical challenges and academic controversies. This review summarizes the current evidence, discussion points, and recommendations regarding the use of immune checkpoint inhibitors (ICIs) in patients with cancer during the SARS-CoV-2 pandemic, with a focus on patients with melanoma and renal cell carcinoma (RCC). More specifically, we summarize the theoretical concepts and available objective data regarding the relationships between ICIs and the antiviral immune response, along with recommended clinical approaches to the management of melanoma and RCC patient cohorts receiving ICIs throughout the course of the COVID-19 pandemic. Additional insights regarding the use of ICIs in the setting of current and upcoming COVID-19 vaccines and broader implications toward future pandemics are also discussed.